Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00262483 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00262483 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 12 participants.
The verdict
NCT00262483, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.
Interventions
- DRUG peginterferon alfa-2a
- DRUG ribavirin
- DRUG VX-950
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00262483
The ClinicalTrials.gov registry entry for NCT00262483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which peginterferon alfa-2a is the first listed.
NCT00262483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00262483 about?
NCT00262483 is a clinical study titled "Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C". To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.
What is the current status of trial NCT00262483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2005-12. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00262483?
The interventions under investigation include: peginterferon alfa-2a (DRUG), ribavirin (DRUG), VX-950 (DRUG).
Who is sponsoring clinical trial NCT00262483?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.